Scientists have discovered a new alternative to Ozempic for combating diabetes.

Scientists from Jiangnan University in China may have discovered a natural method for regulating blood sugar levels and combating sweet cravings, potentially serving as an alternative to medications like Ozempic. Their research, conducted on mice, highlighted the significant role of a specific gut microbe and its metabolites in stimulating the secretion of glucagon-like peptide-1 (GLP-1), as reported by ScienceAlert.

GLP-1 is a hormone that helps regulate blood sugar levels and induces a feeling of fullness. This mechanism is mimicked by GLP-1 agonist medications, such as semaglutide, the active ingredient in Ozempic. In patients with type 2 diabetes, GLP-1 function is often impaired, affecting their ability to control blood sugar levels. Despite the high efficacy of medications like Ozempic, researchers are exploring ways to stimulate the natural production of GLP-1 in the body.

A new study published in the journal Nature Microbiology, led by Tingting Tang, Ph.D. from Jiangnan University, focused on the gut microbiome, particularly the microbe Bacteroides vulgatus and its metabolites as key elements in this process. By increasing the population of B. vulgatus in diabetic mice, the researchers found that they could trigger the secretion of GLP-1, improving blood sugar control and reducing sweet cravings.

Further analysis revealed that the role of the microbe is linked to an intestinal protein called Ffar4. In mice lacking this protein, colonies of B. vulgatus decreased, leading to reduced production of a hormone called fibroblast growth factor 21 (FGF21). This hormone is associated with sugar cravings; studies in humans indicate that individuals with certain genetic variants of FGF21 are more likely to consume large amounts of sugary foods.

Treating mice with a metabolite of B. vulgatus increased the secretion of GLP-1 and FGF21, enhancing blood sugar control and food preferences. The researchers also conducted blood tests on 60 individuals with type 2 diabetes and 24 healthy people. They found that mutations in Ffar4, which disrupt FGF21 production, were linked to a stronger preference for sugar and potentially a higher risk of developing diabetes. This suggests that the gut microbiome plays a central role in regulating eating behavior and metabolic health, representing a possible pathway for diabetes prevention.

While the results obtained from mice are promising, it remains to be seen whether similar effects can be achieved in humans. The authors acknowledge the need for further research in this area but emphasize that their study could lay the groundwork for developing strategies to combat diabetes and sugar cravings through such manipulations of the gut microbiome.

This research complements the growing understanding of the "gut-brain axis" and its role in metabolic health. It also aligns with current studies on gut microbes and their impact on dietary habits and chronic diseases. According to the World Health Organization, more than 420 million people worldwide suffer from diabetes, and innovative solutions like this could offer new hope to millions.

This material is for informational purposes only and does not contain advice that may affect your health. If you are experiencing issues, please consult a specialist.